Teva and Xenon rack up another setback as PhIIb study fails on every endpoint
The bad news is stacking up at Xenon Pharmaceuticals. Its most advanced drug just flopped in a Phase IIb at Teva, just three months after the biotech was forced to concede a stock-crunching Phase II failure for its in-house acne drug.
Teva and Xenon $XENE stuck with the top-line data today, noting that testing TV-45070 in patients with post-herpetic neuralgia failed at the primary as well as secondary endpoints. The failure comes two years after the same drug failed for osteoarthritis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.